Epstein-Barr Virus load and immune activation in Human Immunodeficiency Virus type 1-infected patients

Journal of Clinical Virology

Volumn 53, Issue 3, 2012, Pages 195-200

  Petrara, Maria Raffaella ^a   Cattelan, Anna Maria ^b   Zanchetta, Marisa ^c   Sasset, Lolita ^b   Freguja, Riccardo ^a   Gianesin, Ketty ^a   Cecchetto, Maria Grazia ^b   Carmona, Francesco ^c   De Rossi, Anita ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Hospital of Rovigo   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

B cell activation; EBV; EBV related lymphomas; HIV 1; Immune activation

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; COHORT STUDIES; CYTOKINES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 84856975410     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.12.013     Document Type: Article

References (37)

1. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007, 7:96-101.
2. Beral V., Newton R. Overview of the epidemiology of immunodeficiency-associated cancers. J Natl Cancer Inst Monogr 1998, 23:1-6.
3. Carbone A., Cesarman E., Spina M., Gloghini A., Schulz T.F. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009, 113:1213-1224.
4. Douek D.C., Roederer M., Koup R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009, 60:471-484.
5. Grulich A.E., Wan X., Law M.G., Milliken S.T., Lewis C.R., Garsia R.J., et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2002, 14:133-140.
6. Moir S., Fauci A.S. B cells in HIV infection and disease. Nat Rev Immunol 2009, 9:235-245.
7. Gaidano G., Dalla-Favera R. Molecular pathogenesis of AIDS-related lymphomas. Adv Cancer Res 1995, 67:113-153.
8. Righetti E., Ballon G., Ometto L., Cattelan A.M., Menin C., Zanchetta M., et al. Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 2002, 16:63-73.
9. Burighel N., Ghezzi S., Nozza S., Del Bianco P., Lazzarin A., Tambussi G., et al. Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica 2006, 91:244-247.
10. David D., Bani L., Moreau J.L., Treilhou M.O., Nakara T., Joussemet M., et al. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Natl Acad Sci USA 1998, 95:11348-11353.
11. Macchia D., Almerigogna F., Parronchi P., Ravina A., Maggi E., Romagnani S. Membrane tumor necrosis factor alfa is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 1993, 363:464-466.
12. Mauray S., Fuzzati-Armentero M.T., Trouillet P., Ruegg M., Nicoloso G., Hart M., et al. Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. Eur J Immunol 2000, 30:2065-2073.
13. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
14. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
15. Simard E.P., Pfeiffer R.M., Engels E.A. Cumulative incidence of cancer among individuals with Acquired Immunodeficiency Syndrome in the United States. Cancer 2011, 117:1089-1096.
16. Anselmi A., Vendrame D., Rampon O., Giaquinto C., Zanchetta M., De Rossi A. Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clin Exp Immunol 2007, 150:442-450.
17. Department of Health and Human Services guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescent; December 2007. http://aidsinfo.nih.gov/guidelines.
18. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults; June 2008. http://www.eacs.eu/.
19. Abbate I., Zanchetta M., Gatti M., Gabrielli L., Zanussi S., Milia M.G., et al. Multicenter comparative study of Epstein-Barr virus quantification for virological monitoring in transplanted patients. J Clin Virol 2011, 50:224-229.
20. Ometto L., De Forni D., Patiri F., Trouplin V., Mammano F., Giacomet V., et al. Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS 2002, 16:839-849.
21. Centers for Disease Control and Prevention. HIV Classification: CDC and WHO staging systems; July 2006 (updated April 2009).
22. Cattelan A.M., Calabro M.L., Aversa S.M., Zanchetta M., Meneghetti F., De Rossi A., et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999, 35:1809-1815.
23. Tirelli U., Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer 2001, 37:1320-1324.
24. De Rossi A., Walker A.S., De Forni D., Klein N., Gibb D.M. Relationship between changes in thymic emigrants and cell-associated HIV-1-infected children initiating antiretroviral therapy. Antivir Ther 2005, 10:63-71.
25. Lecossier D., Bouchennet P., Schneider P., Clavel F., Hance A.J. Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001, 183:1009-1016.
26. Gilson R.J., Man S.L., Copas A., Rider A., Forsyth S., Hill T., et al. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2010, 11:152-160.
27. Iskra S., Kalla M., Delecluse H.J., Hammerschmidt W., Moosmann A. Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus. J Virol 2010, 84:3612-3623.
28. He B., Qiao X., Klasse P.J., Chiu A., Chadburn A., Knowles D.M., et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006, 176:3931-3941.
29. Swingler S., Brichacek B., Jacque J.M., Ulich C., Zhou J., Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003, 424:213-219.
30. Wagner M., Poeck H., Jahrsdoerfer B., Rothenfusser S., Prell D., Bohle B., et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 2004, 172:954-963.
31. Aukrust P., Müller F., Lien E., Nordoy I., Liabakk N.B., Kvale D., et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999, 179:74-82.
32. Regidor D.L., Detels R., Breen E.C., Widney D.P., Jacobson L.P., Palella F., et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011, 25:303-314.
33. Stone S.F., Price P., Keane N.M., Murray R.J., French M.A. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002, 3:21-27.
34. Muller M., Wandel S., Colebunders R., Attia S., Furrer H., Egger M., et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:251-261.
35. Kuller L.H., Tracy R., Belloso W., De Wit S., Drummond F., Lane H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5:e203.
36. Gu Y., Shore R.E., Arslan A.A., Koenig K.L., Liu M., Ibrahim S., et al. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control 2010, 21:1323-1333.
37. Vendrame E., Martínez-Maza O. Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. J Proteome Res 2011, 10:113-119.